Chronic kidney disease stages 1–3: screening, monitoring, and treatment.

Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald, R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ
Record ID 32013000778
English
Authors' objectives: The objective was to systematically review and synthesize evidence regarding benefits and harms of screening for and monitoring and treatment of chronic kidney disease (CKD) stages 1–3.
Authors' recommendations: No trials directly show a benefit for CKD screening or monitoring. The likelihood of benefit, if present, appears to be greater in specific subgroups. Screening and monitoring harms are poorly described. In selected CKD patients, ACEI or ARB treatment reduces ESRD risk, ACEI treatment reduces mortality risk, and statin treatment reduces risk of mortality, MI, and stroke. Many of these patients may already warrant treatment with these therapies regardless of CKD status. Many knowledge gaps remain, and additional research should increase understanding regarding optimal approaches to CKD screening, monitoring, and treatment.
Details
Project Status: Completed
Year Published: 2012
URL for published report: http://www.effectivehealthcare.ahrq.gov/ehc/products/163/809/CER37_ChronicKidney_20120321.pdf
URL for additional information: http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=809
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Humans
  • Mass Screening
  • Renal Insufficiency, Chronic
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.